Breast Cancer: MK-3475 as Adjuvant therapy for Triple Receptor-Negative Breast Cancer
or Positive Lymph Nodes After Neoadjuvant Chemotherapy - S1418
Research Question:
Does the drug MK-3475 help the survival of patients with breast cancer?
Basic Study Information
Purpose:
The purpose of this study is to compare treated subjects' invasive disease-free survival
of patients with triple-negative breast cancer after neoadjuvant chemotherapy.
Location: University of Rochester Medical Center
Study Reference #: CBRS18089
Lead Researcher (Principal Investigator)
Lead Researcher:
Alissa Huston
Study Contact Information
Study Coordinator: Laura Mitchell
Phone: (585) 275-7763
Email: Laura_Mitchell@URMC.Rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search